STOCK TITAN

Biorestorative Therapies Inc - BRTX STOCK NEWS

Welcome to our dedicated page for Biorestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on Biorestorative Therapies stock.

BioRestorative Therapies Inc (BRTX) is a pioneering biotechnology company advancing autologous stem cell therapies for chronic disc/spine conditions and metabolic disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate announcements.

Access timely information about BRTX-100 clinical trials, metabolic program research, financial disclosures, and strategic partnerships. Our curated collection ensures transparent tracking of progress in regenerative medicine, featuring official press releases and verified news coverage.

Key focus areas include FDA communications, peer-reviewed study results, intellectual property developments, and executive leadership updates. Users benefit from centralized access to critical information for informed decision-making without promotional bias.

Bookmark this page for ongoing updates on BioRestorative Therapies' innovative work in cell-based medical solutions. Check regularly for new developments in non-surgical treatment alternatives and metabolic health innovations.

Rhea-AI Summary

BioRestorative Therapies (OTC: BRTX) announced the issuance of a significant patent by the Australian Patent Office for its ThermoStem® Program. The patent covers an implantable scaffold using brown adipose-derived stem cells and methods of use to treat metabolic disorders. Initial preclinical research suggests that increased levels of brown fat can enhance caloric burning and reduce glucose and lipid levels, potentially lowering obesity and diabetes risks. The CEO emphasized the patent's importance for delivery methods in ongoing program development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.25%
Tags
none
-
Rhea-AI Summary

BioRestorative Therapies (OTC: BRTX) announced the issuance of a significant patent by the Japanese Patent Office for its ThermoStem® Program, which focuses on methodologies for deriving brown adipocytes from human brown adipose-derived stem cells. The patent underscores the potential of brown fat in improving metabolic processes, including calorie burning and glucose regulation. CEO Lance Alstodt highlighted the growing value of their intellectual property. The company is utilizing stem cell protocols for various therapies, including treatments for disc/spine diseases and obesity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
none
Rhea-AI Summary

BioRestorative Therapies (OTC: BRTX) announces its annual stockholders meeting on August 17, 2021, at 10 a.m. EDT. Key proposals for vote include the reincorporation from Delaware to Nevada and a reverse stock split. Majority approval is required for these changes. Stockholders of record as of June 24, 2021, are encouraged to vote online or attend in person. The company focuses on developing stem cell-based therapies, with lead product BRTX-100 targeting chronic lower back pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
none
-
Rhea-AI Summary

BioRestorative Therapies (OTC: BRTX) announced the filing of a registration statement on Form S-1 with the SEC for a proposed underwritten public offering of its securities. The offering's completion depends on the registration's effectiveness and market conditions. If successful, the net proceeds will fund clinical trials for BRTX-100, research and development for the metabolic ThermoStem Program, and general corporate expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8%
Tags
-
Rhea-AI Summary

BioRestorative Therapies invites investors to attend its presentation at the Emerging Growth Conference on June 9, 2021, at 10:45 AM Eastern Time. The event allows interaction with CEO Lance Alstodt and VP of R&D Francisco Silva. Attendees can ask questions, and a recording will be available post-event. BioRestorative focuses on stem cell therapies, with its leading product BRTX-100 targeting chronic lower back pain. The conference serves as a platform for public companies to present innovative solutions to investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.92%
Tags
conferences
Rhea-AI Summary

BioRestorative Therapies, Inc. (OTC: BRTX) announced the expansion of its Melville, NY research labs for clinical production of cell therapies.

The new cGMP facility will support the Phase 2 clinical trial for BRTX-100 and the ThermoStem® program, enhancing internal manufacturing capabilities.

As part of this initiative, the company plans to hire more employees, aligning operations with FDA and EMA regulations for clinical-grade cell production.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Summary

BioRestorative Therapies, Inc. (OTC: BRTX) announced the filing of its Annual Report on Form 10-K for 2020, achieving compliance with SEC requirements. This filing removed the 'stop sign' from its OTC profile, indicating current public information availability. CEO Lance Alstodt expressed optimism regarding the company's positioning for funding opportunities for its phase 2 clinical trial and advances in its metabolics program. The company emphasizes a focus on clinical programs to drive future value for shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
none
-
Rhea-AI Summary

BioRestorative Therapies (OTC: BRTX) announced the appointment of Dr. Nickolay V. Kukekov to its Board of Directors, effective March 18, 2021. Dr. Kukekov brings extensive experience in the Emerging Growth Lifesciences sector and capital markets, focusing on biotech company growth. His appointment is seen as pivotal for pursuing strategic objectives, including capital raising for the Phase 2 clinical study of BRTX-100, targeting chronic lower back pain. BioRestorative aims to strengthen its market position in stem cell therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
management
Rhea-AI Summary

BioRestorative Therapies, Inc. (OTC: BRTX) announced a notice of allowance from the U.S. Patent Office for a patent related to its ThermoStem® Program, granted on March 22, 2021. This patent involves methodologies for generating exosomes from brown adipose-derived stem cells, which may offer therapeutic benefits in treating various diseases. The exosome market is projected to reach $368 million by 2022. The CEO emphasized the importance of this patent for protecting their intellectual property and driving the company's growth strategy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.14%
Tags
none
Biorestorative Therapies Inc

OTC:BRTX

BRTX Rankings

BRTX Stock Data

12.11M
5.59M
27.7%
13.91%
10.35%
Biotechnology
Services-misc Health & Allied Services, Nec
Link
United States
MELVILLE